前往化源商城

APE1 Inhibitor III

更新时间:2025-08-21 13:17:37

APE1 Inhibitor III结构式
APE1 Inhibitor III结构式
品牌特惠专场
常用名 APE1 Inhibitor III 英文名 APE1 Inhibitor III
CAS号 524708-03-0 分子量 371.52000
密度 N/A 沸点 N/A
分子式 C19H21N3OS2 熔点 N/A
MSDS N/A 闪点 N/A

 APE1 Inhibitor III用途


APE1-IN-1是一种有效的血脑屏障(BBB)渗透性无嘌呤/无嘧啶(AP)核酸内切酶1(APE1)抑制剂,IC50值为2μM。APE1-IN-1可以增强烷基化剂甲基甲烷磺酸盐和替莫唑胺(HY-17364)对癌细胞的细胞毒性[1]。

 APE1 Inhibitor III名称

英文名 N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide
英文别名 更多

 APE1 Inhibitor III生物活性

描述 APE1-IN-1是一种有效的血脑屏障(BBB)渗透性无嘌呤/无嘧啶(AP)核酸内切酶1(APE1)抑制剂,IC50值为2μM。APE1-IN-1可以增强烷基化剂甲基甲烷磺酸盐和替莫唑胺(HY-17364)对癌细胞的细胞毒性[1]。
相关类别
靶点

IC50: 2 μM (APE1)[1]

体外研究 APE1-IN-1(化合物3)在qHTS分析中显示2μM的IC50,在放射示踪切割分析(RIA)中显示12μM的IC 50[1]。APE1-IN-1(0、1、3、10、30或100μM;15分钟)以剂量依赖性方式抑制HeLa全细胞提取物AP部位切割[1]。APE1-IN-1(5-30μM;24小时)对HeLa细胞具有细胞毒性作用,并增强甲磺酸甲酯和替莫唑胺(HY-17364)的活性[1]。细胞毒性试验[1]细胞系:HeLa细胞浓度:5-30μM培养时间:24小时结果:显示出对HeLa的细胞毒性作用,细胞活力在~15μM时降低50%。极大地增强了甲磺酸甲酯(0.4 mM)和替莫唑胺(HY-17364)(1 mM)的活性,最佳协同作用分别出现在~5μM和~10μM。
体内研究 APE1-IN-1(30 mpk;IP;单剂量)具有良好的药代动力学特性[1]。APE1-IN-1(化合物3)(IP;30 mpk)在CD1小鼠中的药代动力学参数[1]。血浆脑t1/2(h)2.1 1脑/血浆21 Cmax(μM)16 217 tmax(h)0.25 0.25 CLogP 2.83动物模型:CD1雄性小鼠(n=3)[1]剂量:30 mpk给药:IP;单剂量结果:显示亲脂性(CLogP=2.8),很容易穿过血脑屏障,B/P比为21。
参考文献

[1]. Rai G, et al. Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. J Med Chem. 2012 Apr 12;55(7):3101-12.

 APE1 Inhibitor III物理化学性质

分子式 C19H21N3OS2
分子量 371.52000
精确质量 371.11300
PSA 101.71000
LogP 4.76060

 APE1 Inhibitor III英文别名

N-(3-Benzo[d]thiazol-2-yl-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide
APE1 Inhibitor III
本网页内容来自不同专业数据源,如对内容有疑义,欢迎联系service1@chemsrc.com。
品牌现货直购
推荐供应商:


查看所有供应商和价格请点击:

APE1 Inhibitor III生产厂家

APE1 Inhibitor III价格

相关化合物: 更多...
Ftase inhibitor III
2710375-18-9
MMP inhibitor III
927827-98-3
PTP Inhibitor III
29936-81-0
Lck Inhibitor III
1188890-30-3
Calpain Inhibitor III
88191-84-8
trypsin inhibitor III, foxtail millet
133335-36-1
Caspase-9 Inhibitor III
403848-57-7
MK-2 Inhibitor III
1186648-22-5
Cdk1/2 Inhibitor III
443798-55-8
3-Amino-4-[2-[4-[[4-[(2-amino-5-methylphenyl)amino]-6-chloro-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]diazenyl]-5-hydroxy-2,7-naphthalenedisulfonic acid
1184179-32-5
I+/--L-Arabinofuranoside, [1,2,3,4-tetrahydro-7-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-6-methoxy-2-naphthalenyl]methyl, [1S-(1I+/-,2I(2),3I+/-)]-
63358-10-1
(4aR,4bS,6aS,7S,9aR)-N-[2,5-Bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a-decahydro-4a,6a-dimethyl-2-oxo-1H-indeno[5,4-f]quinoline-7-carboxamide
1430804-90-2
L-Proline, 1-[(2S)-3-[[(2R,3S,4S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-4-yl]thio]-2-methyl-1-oxopropyl]-, methyl ester
2227330-50-7
3-[2-[4-[2-[5-Cyano-2-[(2-hydroxyethyl)amino]-4-methyl-6-[(phenylmethyl)amino]-3-pyridinyl]diazenyl]-2,5-dimethylphenyl]diazenyl]benzenesulfonic acid
1173301-37-5
Benzoic acid, 2,4-dihydroxy-6-methyl-, (2R,2aR,4aS,7aS,7bR)-2,2a,4a,5,6,7,7a,7b-octahydro-2a-hydroxy-6,6,7a-trimethyl-1H-cyclobut[e]inden-2-yl ester
139051-16-4
N-[7-[(6-Deoxy-5-C-methyl-4-O-methyl-I+/--L-lyxo-hexopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methylbutyl)benzamide
115294-13-8
Carbamic acid, [(1S)-1-methyl-2-[[(1S,2R)-1-methyl-2-(4-methylphenyl)-2-[(phenylmethyl)amino]ethyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester
874013-84-0
3-[2-(3-Chlorophenyl)diazenyl]-6-[2-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)diazenyl]-4,5-dihydroxy-2,7-naphthalenedisulfonic acid
110952-75-5
O-3-Deoxy-4-C-methyl-3-(methylamino)-I(2)-L-arabinopyranosyl-(1a6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-I+/--D-erythro-hexopyranosyl-(1a4)]-D-streptamine
60768-16-3